Although GLP‐1 RAs such as liraglutide, exenatide, and semaglutide showed potential for improving mental health outcomes—particularly depressive symptoms, anhedonia, anxiety, and quality of life—these preliminary signals require confirmation through larger, methodologically rigorous trials. This evidence concerns the gene GCG and Anxiety.